Loading…
3 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2019 | Percentile | Sector n |
|---|---|---|---|---|
| Aversi-Pharma | Pharma | 13.2% | 51st pct | 102 |
| Aversi-Rational | Pharma | 6.5% | 35th pct | 102 |
| Natusana | (unclassified) | -92.6% | 5th pct | 1052 |
Percentile is within each company's own sector across the whole FY2019 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2019 | Aversi-Pharma | Aversi-Rational | Natusana |
|---|---|---|---|
| Margins | |||
| Gross Margin | 38.3% | 37.6% | 13.0% |
| EBITDA Margin | 13.2% | 6.5% | -92.6% |
| EBITDAR | 60,268 | 2,177 | -237 |
| EBITDAR Margin | 13.2% | 6.5% | -91.0% |
| EBIT Margin | 7.8% | 6.5% | -92.6% |
| Net Profit Margin | 4.2% | 7.2% | -92.3% |
| Operating Expense % of Sales | 25.9% | 31.1% | 105.6% |
| Returns | |||
| Return on Assets (ROA) | 4.2% | 8.0% | -29.0% |
| Return on Equity (ROE) | 8.0% | 25.9% | -29.5% |
| ROIC [EBIT / Invested Capital] | 10.6% | 23.3% | -29.6% |
| Leverage & debt balances | |||
| Debt-to-Assets | 23.2% | 0.0% | 0.0% |
| Debt-to-Equity | 0.44x | 0.00x | 0.00x |
| Debt-to-EBITDA | 1.76x | 0.00x | N/A |
| Equity-to-Assets | 52.7% | 30.8% | 98.3% |
| Net Debt | 94,433 | -115 | -1 |
| Cash & Equivalents | 11,755 | 115 | 1 |
| Total Debt | 106,188 | N/A | N/A |
| Liquidity & working capital | |||
| Current Ratio | 1.52x | 0.95x | 80.78x |
| Quick Ratio | -842.16x | 0.57x | 80.58x |
| Cash Ratio | 85.94x | 0.01x | 0.05x |
| Total Current Assets | 207 | 18,415 | 828 |
| Total Current Liabilities | 137 | 19,358 | 10 |
| Inventory | 115,403 | 7,431 | 2 |
| Trade Receivables | 65,196 | 8,382 | 825 |
| Trade Payables | 74,963 | 3,541 | 10 |
| Net Working Capital | 71 | -943 | 818 |
| Net Working Capital % of Revenue | 0.0% | -2.8% | 314.3% |
| Trade Working Capital | 105,636 | 12,272 | 817 |
| Trade Working Capital % of Revenue | 23.1% | 36.4% | 314.1% |
| Change in Trade Working Capital | N/A | N/A | N/A |
| Turnover & efficiency | |||
| Inventory Turnover | 2.44x | 2.83x | 109.10x |
| Days Inventory Outstanding (DIO) | 149.5 | 129.0 | 3.3 |
| Receivables Turnover | 7.00x | 4.02x | 0.32x |
| Days Sales Outstanding (DSO) | 52.1 | 90.8 | 1157.8 |
| Payables Turnover | 3.76x | 5.94x | 22.09x |
| Days Payable Outstanding (DPO) | 97.1 | 61.5 | 16.5 |
| Cash Conversion Cycle | 104.5 days | 158.3 days | 1144.6 days |
| Asset Turnover | 1.00x | 1.10x | 0.31x |
| Cash flow & dividends | |||
| Operating Cash Flow | 37,624 | 2,759 | -1 |
| Free Cash Flow (OCF − Capex proxy) | 8,191 | 1,880 | -1 |
| Cash Conversion (OCF / EBITDA) | 62.4% | 126.7% | N/A |
| Dividends Declared | 4,000 | 5,000 | 0 |
| Dividend Payout Ratio | 20.7% | 204.8% | N/A |